Anatara Lifesciences : AGM CEO Presentation

About this update from Anatara Lifesciences Ltd

ersonal use only AGM NOVEMBER 2021 ---------------- ASX: ANR influence on their lives 1 Irritable Bowel Syndrome (IBS) is the most commonly diagnosed gastrointestinal condition and a significant cost burden on health care 40% of global consumers say digestive complaints have had some Developing the next generation of gastrointestinal health only products • More than ever, the world is looking for safe and effective solutions for gastrointestinal tract (GIT or 'gut') symptoms and disorders • use • • The Anatara team is focused on delivering evidence-based treatments and solutions for gastrointestinal health needs in humans and animals ersonal • Anatara aims to assist the homeostasis of the "gut" to promote overall health and wellbeing • Commencing clinical trials in FY22, with fast potential speed to market • Strong pre-clinical data for Inflammatory Bowel Disease (IBD) 1. https://nutraceuticalbusinessreview.com/news/article_page/A_good_gut_feeling_why_digestive_health_is_the_next_wellness_frontier/177171 Achievements only Human health assets Achievements • All components GRAS (FDA: generally regarded as safe) • Patent pending formulation with functional use coatings of synergistic combination of components • Achieved clinical trial ethics approvals: GaRP and 3FDC • GMP clinical batches manufactured and released ersonal for clinical trial • Clinical trial - Irritable Bowel Syndrome • Commenced August 2021 • Clinical trial - Psychological Functioning • Commencing late November 2021 Animal health assets Achievements Detach® patents granted in Australia and Japan Developed new bromelain-based formulations to offer convenient delivery options (in-feed, in- water) and for new species (poultry, aquaculture) ANR-pf: challenge trial in poultry for subclinical and necrotic enteritis successfully completed BONIFF + Ridley's SMEC: Challenge trial in piglets for enterotoxigenic Escherichia coli completed Program pipeline only PRECLINICAL CLINICAL COMMERCIAL PROGRAM DELIVERY DISCOVERY REGISTRATION In-Vivo Proof of RIGHTS In-Vitro Pivotal (animal) Concept Irritable Bowel Syndrome (Diarrhoea) GaRP 18-65 Oral ✓ ✓ ✓ Mar '22 Sep '22 Global Minitabs HUMAN use Moderate Depression, Anxiety or Stress 3FDC 15-55 Oral ✓ ✓ ✓ * Apr '22 Global Minitabs Scour (diarrhoea) Detach® Piglets Oral ✓ ✓ ✓ ✓ ✓ Australia (APVMA) Global Drench ersonal ANIMAL BONIFF Piglets Oral ✓ ✓ ✓ ✓ Global In-feed Subclinical & Clinical Necrotic Enteritis ANR-pf Chicks Oral ✓ ✓ ✓ ✓ Global In-water * Third party published studies on individual components of 3FDC Building a Health Portfolio • Anatara aims to be the 'go to' company for gut health solutions, including treatments, diagnostics and advice only • Focused on delivering evidence-based treatments and solutions for GIT health needs GaRP Technology to provide a pipeline of products • Potential to apply our GaRP technology into other GIT conditions, IBD in particular, and several largely unaddressed paediatric indications use • 3FDC is a combination of some components of GaRP used specifically for psycho-emotional indications Presently evaluating diagnostics and other GIT therapeutic opportunities ersonal • To offer consumers and patients broader solutions to GIT complaints • To diversify Anatara's portfolio of GIT health solutions • We anticipate initiating one of these opportunities in the next 6 months This is an excerpt of the original content. To continue reading it, access the original document here .

View stock analysis, news, and events for Anatara Lifesciences Ltd